母体普萘洛尔治疗胎盘绒毛膜血管瘤或可替代侵入性胎儿手术
本文报道4例在荷兰莱顿大学医学中心就诊、合并大型绒毛膜血管瘤并出现胎儿失代偿征象的胎儿,给予母体口服普萘洛尔治疗后胎儿情况均显著改善。绒毛膜血管瘤可因高输出量心力衰竭导致胎死宫内,而标准侵入性治疗成功率有限且胎儿死亡率高;普萘洛尔已用于婴儿血管瘤,为治疗症状性或快速生长的胎盘绒毛膜血管瘤提供了依据。
要点
- 绒毛膜血管瘤可致高输出量心力衰竭和胎儿死亡,侵入性治疗风险高。
- 4例胎儿经母体普萘洛尔治疗后心功能恢复、水肿消退、肿瘤缩小并血栓形成。
- 母体普萘洛尔有望成为症状性绒毛膜血管瘤的非侵入性治疗选择。
核心结论
- 母体口服普萘洛尔可使合并大型绒毛膜血管瘤并胎儿失代偿的胎儿病情显著改善,支持将其作为减少操作风险的替代治疗方向。
主要发现
- 4例胎儿经普萘洛尔治疗后胎儿情况均显著改善,心功能恢复正常、水肿消退,并伴肿瘤缩小和组织学证实的血栓形成。
临床怎么用
- 对合并大型绒毛膜血管瘤且出现高动力循环或水肿等失代偿征象的胎儿,可考虑母体普萘洛尔这一超说明书用药方案,但需在充分评估后个体化使用。
局限性
- 仅为4例病例系列,证据级别有限,尚需更大样本研究验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chorioangiomas are associated with a significant risk of fetal demise due to high-output cardiac failure. Standard invasive treatment, including fetoscopic laser photocoagulation and intratumoral embolization, shows limited success and has high fetal mortality rates. The biological parallels between chorioangiomas and infantile hemangiomas suggest that these tumors may share common therapeutic targets. Propranolol is a proven therapy for infantile hemangiomas, therefore this established efficacy provides a strong rationale for its consideration in the management of symptomatic or rapidly growing placental chorioangiomas. We hypothesized that maternal oral propranolol administration could selectively target placental chorioangiomas while preserving overall placental function, thereby offering a potential off-label therapeutic use of the drug. We report a case series of four fetuses that presented to Leiden University Medical Center, Leiden, The Netherlands, between December 2023 and May 2025 with a large chorioangioma and signs of fetal decompensation, varying from hyperdynamic circulation to evolving hydrops, and were treated with maternal propranolol. In all four cases, the fetal condition improved significantly upon propranolol treatment, with normalization of cardiac function and resolution of hydrops, paralleled by tumor regression and thrombosis confirmed histologically. These findings support a shift in the clinical management of chorioangiomas to improve fetal outcomes while minimizing procedural risks. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- van der Meeren LE, Slaghekke F, Zaaijer S, et al. Maternal propranolol as a safe alternative to invasive fetal surgery in chorioangioma management. Ultrasound Obstet Gynecol. 2026. PMID: 42406825. doi:10.1002/uog.70272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。